VanEck Genomics and Healthcare Innovators UCITS ETF

CURE · IE000B9PQW54 · VanEck

Overview

VanEck Genomics and Healthcare Innovators UCITS ETF targets companies linked to a specific investment theme, making it narrower than a diversified global equity ETF. The fund has a very low TER of 0.35%.

Key facts

Ticker

CURE

ISIN

IE000B9PQW54

Provider

VanEck

TER (ongoing charge)

0.35%

Benchmark

Not currently available

Fund domicile

Ireland

UCITS status

ucits

Asset class

Equity

Benchmark & strategy

Benchmark

Not currently available

Index tracked

Not currently available

Replication

Not currently available

Costs & size

AUM

$13.4M · as of 24 Jul 2026

AUM currency

USD

Risk & fund structure

Launch date

2 Sept 2022

Replication method

Not currently available

Share class currency

USD

Currency exposure

Not currently available

SFDR

Article 9

Official Documents

Official product page — VanEck ↗Official factsheet — VanEck ↗Official Key Information Document — VanEck ↗

These primary-source links open on the ETF provider’s website.

Listings

CURENot currently available

Data provenance

Source: Not currently available

Source last checked: 27 Jul 2026

Record last updated: 27 Jul 2026

Enrichment status: imported

Compare with other ETFs All VanEck ETFs All providers

Continue researching

Related Grovcap guides, rankings and tools to take the next step.

BenchmarkS&P 500 benchmark guideUnderstand the coverage and limits behind S&P 500 ETFs.BenchmarkMSCI World benchmark guideUnderstand developed-market coverage and exclusions.ETF comparisonCSPX vs VUAATwo accumulating Irish-domiciled S&P 500 trackers compared side by side.ETF comparisonIWDA vs VWCEDeveloped-world versus all-world coverage, cost and portfolio fit.ETF comparisonVWCE vs WEBNFTSE and Solactive all-country implementations compared.

Disclaimer

The information provided by Grovcap is for informational and educational purposes only and does not constitute investment, financial, legal, or tax advice. Investing involves risk, including the possible loss of capital. Always conduct your own research or consult a qualified professional before making investment decisions.

Your responses to quizzes, surveys, and other interactive features may be used in aggregated and anonymized form to improve Grovcap and generate investor insights. We do not sell personally identifiable information to third parties. For more information about how we collect, use, and protect your data, please refer to our Privacy Policy.